In this article, we will discuss about Anastrozole (Dosage). So, let’s get started.
Indications
Adjuvant Treatment
Anastrozole (ARIMIDEX®) is indicated for adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer.
First-Line Treatment
Anastrozole (ARIMIDEX®) is indicated for the first-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer.
Second-Line Treatment
Anastrozole (ARIMIDEX®) is indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. Patients with ER-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to
Anastrozole (ARIMIDEX®).
Dosage
Recommended Dose
The dose of Anastrozole (ARIMIDEX®) is one I mg tablet taken once a day. For patients with advanced breast cancer, Anastrozole (ARIMIDEX®) should be continued until tumor progression, Anastrozole (ARIMIDEX®) can be taken with or without food.
For adjuvant treatment of early breast cancer in postmenopausal women, the optimal duration of therapy is unknown. In the ATAC trial, Anastrozole (ARIMIDEX®) was administered for five years.
No dosage adjustment is necessary for patients with renal impairment or for elderly patients.
Patients with Hepatic Impairment
No changes in dose are recommended for patients with mild-to-moderate hepatic impairment. Anastrozole (ARIMIDEX®) has not been studied in patients with severe hepatic impairment.
Warnings and Precautions
• In women with pre-existing ischemic heart disease, an increased incidence of ischemic cardiovascular events
occurred with Anastrozole (ARIMIDEX®) use compared to tamoxifen use. Consider risks and benefits.
• Decreases in bone mineral density may occur. Consider bone mineral density monitoring.
• Increases in total cholesterol may occur. Consider cholesterol monitoring.
Adverse Reactions
In the early breast cancer (ATAC) study, the most common (occurring with an incidence of >10%) side effects occurring in women taking Anastrozole (ARIMIDEX®) included: hot flashes, asthenia, arthritis, pain, arthralgia, pharyngitis, hypertension, depression, nausea and vomiting, rash, osteoporosis, fractures, back pain, insomnia, headache, peripheral edema and lymphedema,
regardless of causality.
In the advanced breast cancer studies, the most common (occurring with an incidence of >10%) side effects occurring in women taking Anastrozole (ARIMIDEX®) included: hot flashes, nausea, asthenia, pain, headache, back pain, bone pain, increased cough, dyspnea, pharyngitis and peripheral edema.